Oligos explainer: A new frontier in precision medicine, highlights the transformative potential of oligonucleotide therapies. These precision medicines, which use short DNA or RNA molecules to target specific genes, offer groundbreaking solutions for diseases previously deemed untreatable, from rare genetic disorders to cancer.
Maxion Therapeutics (”Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, announced today that it has raised $72 million (£58 million) in a Series A financing.
Up to 70,000 new jobs will be needed in the UK life sciences sector over the next decade to unlock its potential in growing the UK economy, according to a new report.
New Women in Biotech leadership report is first in comprehensively collecting and examining C-suite gender leadership data for UK biotech. The report identifies clear successes of female leadership at the same time as highlighting sustained challenges.
The UK biotech sector soared in 2024, raising £3.5 billion—a 94% surge—evidencing its resilience, global appeal, and untapped potential for UK investors amidst calls for pension reform.
BIA today announces Blood Cancer UK as its charity partner of the year for 2025. This partnership demonstrates BIA’s commitment to driving meaningful change through collaboration.
Dr Mahony will work with the UK Government to champion investment into the UK’s innovative life sciences and biotech sector, including playing a key role in the ongoing pension reforms led by Chancellor Rachel Reeves MP.
BIA, MedCity, and London & Partners announce the launch of London Life Sciences Week (LLSW), celebrating the UK’s thriving life sciences ecosystem and bringing together international investors, industry leaders, and cutting-edge innovators.
Read our statement welcoming the Chancellor's recommitment to R&D tax credits, new funding initiatives, and sustained support for biotechnology and medical science.
The UK biotech sector secured an impressive £808 million in Q3 2024, defying tough global market conditions and demonstrating sustained investor confidence. Read our latest report to find out more.
A new group of MPs and peers, with the support of the BioIndustry Association (BIA), has written to the Chancellor, urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget.
The UK is a global leader in TechBio, drawing substantial investments and nurturing a vibrant ecosystem of talent and businesses, reveals a report launched today by the BIA.
The Chancellor’s Budget on 30 October is an opportunity to end short-termism, cut waste, and attract long-term investment to the UK economy with a sector-targeted R&D tax relief policy. However, changes should not be rushed and must be based on the best economic evidence.
The UK Bioindustry Association (BIA) has today joined the European Biosolutions Coalition, adding UK representation to this influential group. The European Biosolutions Coalition is an initiative established by several industry organisations to elevate the prominence of biosolutions on the European agenda.
The Francis Crick Institute’s start-up accelerator KQ Labs and the UK Bioindustry Association (BIA) have launched a new programme to support growing companies working at the interface of biology and data technologies.
New report 'State of the Discovery Nation: Fostering a Dynamic, Sustainable Medicines Discovery Sector’ says the sector must work together to de-risk funding in medicines discovery and attract more investors.
BIA is gearing up for a prominent presence at SynBioBeta 2024, the world's leading conference for engineering biology. The BIA is leading a coalition of UK stakeholders to showcase the dynamism and innovation of the UK's engineering biology companies from 6-9 May in San Jose, California.
Importers of laboratory reagents and materials used in the manufacture of medicines in the UK’s life sciences sector have been given a six-month extension to make the necessary changes to their supply chains for new post-Brexit border paperwork and border inspections.
